Beyond GLP-1s: Why Effective Obesity Care Requires More Than Medication
Authors of a narrative review examining global obesity trends and prevention strategies through 2026 highlights the growing need for treatment strategies that address the biological, behavioral, and environmental drivers of obesity. The authors identify ultra-processed food consumption, physical inactivity, socioeconomic disparities, genetic susceptibility, gut microbiota changes, and chronic inflammation as contributors to rising obesity prevalence, particularly in low- and middle-income countries. Evidence summarized from randomized trials and meta-analyses supports combining nutritional interventions, physical activity, behavioral therapy, and pharmacologic treatment to improve weight and metabolic outcomes. The review reports average body mass index reductions of approximately 1.5 to 3.5 kg/m² with multicomponent lifestyle interventions, while newer incretin-based therapies have produced substantially greater weight loss in clinical trials. The authors also highlight functional foods, including fiber-rich millets and other whole grains, as potentially useful dietary components for improving satiety and metabolic health, although evidence for their specific role in obesity treatment remains limited.
The authors reinforce the importance of individualized, long-term obesity management that extends beyond calorie restriction or medication alone. Comprehensive care may include dietary counseling, regular physical activity, behavioral support, assessment of obesity-related comorbidities, and consideration of anti-obesity medications or bariatric surgery when clinically appropriate. Incorporating affordable, nutrient-dense foods and addressing barriers such as food insecurity, limited access to care, and inadequate opportunities for physical activity may improve the feasibility of treatment plans. The authors also emphasize prevention through healthier food environments, nutrition education, and expanded access to evidence-based care. However, this is a narrative synthesis rather than a new clinical trial or formal meta-analysis, and the benefits attributed to specific functional foods and population-level interventions require further confirmation. Larger, longer-term studies are needed to clarify treatment durability, safety, cost-effectiveness, and the role of emerging dietary approaches alongside established obesity therapies.
Reference: Kushwah P, Kumar R, Srivastava I, et al. Obesity in 2026: analyzing the rapid rise and pathways to prevention. Int J Pharm Sci. 2026 Feb;4(2):824-838. doi: 10.5281/zenodo.18494036.
Kristin Kamprath
MPAS, PA-C